Skip Navigation Links Glaucoma > Glaucoma News

Glaucoma News

8/26/2010

Kowa Optimed Announces Ronald Kaiser As Vice President Of Medical Sales

Kowa Optimed, Inc., a leading innovator of integrated ophthalmic diagnostic systems, has named Ronald Kaiser as its newly appointed Vice President of Medical Sales effective September 1st, 2010. A well-accomplished writer and lecturer, bringing over 36 years of experience in the Medical/ Ophthalmic field, Kaiser is ideally suited to lead Kowa Optimed's medical sales team, as well as directly contribute to the company's overall growth. Kaiser most recently served as the National Sales and Marketing Manager at Canon U.S.A. Inc., where he was responsible for Sales activities in the USA, Latin America and Canada as well as new product development projects and new business opportunities.

Source: Kowa Optimed, Inc.


8/20/2010

No Role For C-Reactive Protein In Pseudoexfoliation Syndrome

While pseudoexfoliation is likely a systemic disorder, serum levels of C-reactive protein appear to be no different in patients with pseudoexfoliation syndrome, pseudoexfoliation glaucoma or control patients, according to a study.

Source: Ocular Surgery News


8/19/2010

Poverty - Not Sight Loss - Explains Low Quality Of Life For Visually Impaired People, Says New Research

In a startling reversal of popular assumptions new research commissioned by Thomas Pocklington Trust shows that when people with sight loss suffer depression and low quality of life it is more to do with low incomes, ill health and lack of social participation, than it is to do with their loss of vision.

Source: Medical News Today


8/18/2010

IRIDEX Granted U.S. Patent For MicroPulse Technology - A Fine Dose Control Technology Enabling Tissue Sparing Eye Surgeries With Visible Lasers

IRIDEX Corporation today announced the receipt of issuance of U.S. Patent No. 7,771,417, titled "Laser System with Short Pulse Characteristics And Its Method Of Use." This patent applies to the company's MicroPulse technology which provides the ophthalmologist with fine dose control of laser energy during eye surgery. Ophthalmologists are using MicroPulse technology to treat patients suffering from diabetic retinopathy and other sight-threatening retinal and glaucoma disorders. Treatments using MicroPulse technology demonstrate favorable outcomes and significantly less damage to healthy retinal structures compared to traditional continuous wave laser treatment.

Source: IRIDEX Corporation


8/13/2010

Obesity Linked To Lower Risk Of Glaucoma In Women

A recent study found that heavier women were less likely to get one type of glaucoma than their thinner peers - the first time this association has been shown, the authors report.

Source: Reuters Health


8/12/2010

Topcon Enters Therapeutic Laser Market, Acquires Retina And Glaucoma Business Of OptiMedica

Topcon Corporation announces that it has signed a definitive agreement to purchase the glaucoma - and retina - related assets of OptiMedica Corporation (Santa Clara, CA,USA).

Source: Topcon Medical Systems, Inc.


8/11/2010

FedEx Delivers Two Sight-Saving Programs In Southeast Asia Through ORBIS Flying Eye Hospital

Vietnam and the Philippines Set to Receive Ophthalmic Skills Exchange Programs from FedEx Sponsorship of ORBIS Program

Source: ORBIS International


8/11/2010

NeoStem And The Schepens Eye Research Institute To Study NeoStem's VSEL(TM) Technology In Retinal Diseases

NeoStem, Inc. ("NeoStem" or the "Company"), an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the Schepens Eye Research Institute, a charitable corporation of Massachusetts and an affiliate of Harvard Medical School. NeoStem will collaborate with the Schepens Institute and sponsor research in the laboratories of principal investigators Drs. Michael Young, Ph.D., Director of the Institute's Minda de Gunzburg Center for Ocular Regeneration, and Kameran Lashkari, M.D. The focus of the research will be on the development of therapies for both age-related macular degeneration (AMD) and Glaucoma.

Source: NeoStem, Inc.


8/11/2010

OptiMedica Sells Retina And Glaucoma Business To Topcon, Sharpens Focus On Laser Cataract Surgery Market

Global ophthalmic device company OptiMedica Corp. has announced that it has signed a definitive agreement to sell its retina and glaucoma assets to Topcon Corp., a strategic move that positions OptiMedica to focus exclusively on the continued development and commercialization of advanced technologies for the treatment of cataract. The largest acquisition by Topcon's medical division to date, the sale provides OptiMedica with significant additional funding for the global market launch of its laser cataract surgery system as well as continued cataract-focused research and development.

Source: OptiMedica Corp.


8/10/2010

Study Identifies Factors Associated With Rate Of Visual Field Change In Patients With Glaucoma

Patients with glaucoma appear to have more rapid visual field change if they are older or if they have abnormal levels of anticardiolipin antibody (an antibody directed against a certain protein in the body), according to a report posted online today that will appear in the October print issue of Archives of Ophthalmology, one of the JAMA/Archives journals. Reducing intraocular pressure—the pressure within the eyeball—modestly in these patients appears to ameliorate the rate at which they experience declines in visual field.

Source: JAMA and Archives Journals

Next Page

Sponsored by

The most likely diagnosis is:




 
advertisement
Here"s the HTML to use:

You do not have JavaScript enabled or are using an older version of Adobe Flash. You can update your version of Adobe Flash here.

Upcoming Events

XXVIII Congress of the European Society of Cataract and Refractive Surgeons (ESCRS)

XXVIII Congress of the European Society of Cataract and Refractive Surgeons (ESCRS)

Sep 04 - Sep 08, 2010

Paris, France

More Information

More Events

Newsletters



Write For Us

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing